Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trialYuankai Shi, Peng Liu, Zhengming Jin et al.|The Lancet Haematology|2019Cited by 248
Genomic and Transcriptomic Characterization of Natural Killer T Cell LymphomaJie Xiong, Weili Zhao, Bowen Cui et al.|Cancer Cell|2020Cited by 234
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimabYuankai Shi, Bo Peng, Hang Su et al.|EBioMedicine|2020Cited by 41
Knockdown of immature colon carcinoma transcript�1 induces suppression of proliferation, S-phase arrest and apoptosis in leukemia cellsGuang-Yao Li, Ming Hou|Oncology Reports|2018Cited by 3